European Society of Cardiology
Clinical Trials
7
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Chronic Coronary Syndrome Snapshot Study
- Conditions
- Chronic Coronary Syndrome
- First Posted Date
- 2024-12-27
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- European Society of Cardiology
- Target Recruit Count
- 4000
- Registration Number
- NCT06748924
- Locations
- 🇦🇲
Erebouni Medical Center, Yerevan, Armenia
SCAD : a Registry of Spontaneous Coronary Artery Dissection
- Conditions
- Spontaneous Coronary Artery Dissection
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- European Society of Cardiology
- Target Recruit Count
- 1500
- Registration Number
- NCT06601270
- Locations
- 🇦🇷
ICBA - Instituto Cardiovascular de Buenos Aires, Buenos Aires, Argentina
🇦🇹Medical University of Innsbruck, Internal Medicine III, Innsbruck, Austria
🇦🇹Klinik Landstrasse, Vienna, Austria
European Survey of Cardiovascular Disease Prevention, Diabetes and Chronic Kidney Disease (EUROASPIRE VI)
- Conditions
- Unstable AnginaST Elevation Myocardial InfarctionCoronary DiseaseNon-ST Elevation Myocardial InfarctionAcute Coronary Syndrome
- First Posted Date
- 2024-07-10
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- European Society of Cardiology
- Target Recruit Count
- 8000
- Registration Number
- NCT06495177
- Locations
- 🇹🇷
Istanbul University, Cerrahpaşa Cardiology Institute, Istanbul, Turkey
Snapshot Study on Patients With Heart Failure
- Conditions
- Heart Failure
- First Posted Date
- 2024-06-24
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- European Society of Cardiology
- Target Recruit Count
- 4000
- Registration Number
- NCT06469814
Stroke Prevention and Rhythm Control Therapy STEEER-AF
- Conditions
- Atrial Fibrillation
- First Posted Date
- 2020-05-20
- Last Posted Date
- 2024-06-20
- Lead Sponsor
- European Society of Cardiology
- Target Recruit Count
- 1732
- Registration Number
- NCT04396418
- Locations
- 🇫🇷
CHU Rennes, Rennes, 'Ille-et-Vilaine, Brittany, France
🇫🇷CHU La Timone, Marseille, Bouches-du-Rhône, France
🇫🇷CHU Dijon - Hôpital du Bocage, Dijon, Burgundy, France
- Prev
- 1
- 2
- Next
News
Pharmaceutical-Grade Cannabidiol Shows Promising Cardiac Safety Profile in High-Risk Patients
A pharmaceutically manufactured cannabidiol formulation demonstrated a favorable cardiac safety profile in patients with cardiovascular risk factors, according to research presented at Heart Failure 2025.
€26.2 Million GREG Initiative Launches to Transform Real-World Evidence Practices Across Europe
The GREG initiative, a five-year €26.2 million public-private partnership, has launched to advance Real-World Evidence practices for medicines and medical devices evaluation across Europe.
Antidepressants Linked to Increased Risk of Sudden Cardiac Death, Danish Study Reveals
New research from Denmark shows antidepressant use is associated with an increased risk of sudden cardiac death, with risk rising based on duration of exposure.
Study Confirms Immediate CPR Saves Lives Regardless of Provider Training
New research from the University of Trieste shows prompt CPR initiation significantly improves cardiac arrest survival rates, regardless of whether performed by bystanders or medical professionals.
FRESH-UP Trial Challenges Fluid Restriction Guidelines in Chronic Heart Failure Patients
The FRESH-UP randomized trial found that liberal fluid intake in chronic heart failure patients did not significantly improve health status compared to fluid restriction, with a mean difference of 2.17 points in KCCQ-OSS scores (p=0.06).
CATHEDRAL-HF Trial Explores Carvedilol Monotherapy in Heart Failure with Improved Ejection Fraction
The CATHEDRAL-HF trial investigated carvedilol as a single maintenance therapy for heart failure (HF) patients with improved ejection fraction (EF).
ABYSS Trial: No Significant Difference in Outcomes Between Continuing or Stopping Beta-Blockers Post-MI
The ABYSS trial investigated the impact of interrupting versus continuing beta-blocker treatment in post-myocardial infarction patients with preserved ejection fraction.
Leading Cardiologist Deepak Bhatt Highlights Critical Challenges in Clinical Trial Interpretation
Dr. Deepak Bhatt, Director of Mount Sinai Heart, addressed key pitfalls in clinical trial interpretation at ESC Congress 2024, drawing from his extensive experience leading landmark cardiovascular trials.